Abeona Therapeutics Inc. (ABEO)
NASDAQ · Manufacturing · Pharmaceutical preparations
$5.40−$0.0300 (−0.55%) on the dayAs of the close; data may be delayed.
ABEO price, last 12 months
Key stats
- Previous close
- $5.43
- Open
- $5.45
- Day range
- $5.34 – $5.48
- 52-week range
- $4.00 – $7.65
- Volume
- 720.7K
- Avg volume (20 days)
- 1.4M
- Market cap
- $308.8M
Performance
1W−3.1%
1M−10.2%
3M−3.7%
6M+24.7%
YTD+2.5%
1Y−2.7%
vs S&P 500, 1Y−19.5 pts
Technicals and fundamentals
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $308.8M